Royal Jelly for Anti-Inflammatory

Research suggests that royal jelly possesses meaningful anti-inflammatory properties, with studies identifying several likely mechanisms including its fatty acids (particularly 10-hydroxy-2-decenoic acid), proteins, flavonoids, and extracellular vesicles acting on key inflammatory signaling pathways such as NF-κB and MAPK to reduce markers like TNF-α, nitric oxide, and interleukins. The evidence base consists primarily of laboratory cell studies, animal models, and narrative reviews rather than large-scale human clinical trials, with findings generally pointing in a supportive direction across a range of inflammatory contexts including kidney injury, skin inflammation, neuroinflammation, and conditions such as rheumatoid arthritis and inflammatory bowel disease. Studies indicate that hydrolyzed royal jelly peptides may be more biologically active than the whole protein, and that extracellular vesicles isolated from royal jelly appear to carry a significant portion of its therapeutic effects. However, the predominance of preclinical and review-level evidence, along with the absence of robust randomized controlled trials in humans, means these findings should be regarded as promising but not yet conclusive, and researchers across multiple reviews consistently call for more rigorous clinical investigation before firm therapeutic claims can be made.